Background The natural history of pulmonary Langerhans cell histiocytosis (PLCH) has been
unclear due to the absence of prospective studies. The rate of patients who experience an …

The French national cohort of children with Langerhans cell histiocytosis ( LCH ) has included
1478 patients since it was established in 1983. LCH therapeutic strategies substantially …

The mitogen-activated protein kinase (MAPK) pathway is constantly activated in Langerhans
cell histiocytosis (LCH). Mutations of the downstream kinases BRAF and MAP2K1 mediate …

Background Vinblastine is the standard treatment for children with Langerhans cell histiocytosis
(LCH). Whether this treatment could be extended to adults with LCH is questionable. …

Purpose The standard evaluation of multisystem Langerhans cell histiocytosis (LCH) includes
a clinical evaluation, laboratory tests and a skeleton/skull X-ray survey, with chest high-…

The clinical significance of the BRAF V600E mutation in adult Langerhans cell histiocytosis (LCH),
including pulmonary Langerhans cell histiocytosis (PLCH), is not well understood. …

Background The long-term outcomes of adult pulmonary Langerhans cell histiocytosis (PLCH),
particularly survival, are largely unknown. Two earlier retrospective studies reported a …

Low-molar-mass organogelators (LMOG) can turn liquids into thermoreversible gels
because they self-assemble into a fibrous network. In contrast, using the same kind of low-molar-…

Background An important objective on diagnosis of patients with Langerhans cell histiocytosis
(LCH) is to determine the extent of disease. However, whether systematic extrathoracic …

Background Pneumothorax may recur during pulmonary Langerhans cell histiocytosis (PLCH)
patients’ follow-up and its management is not standardised. The factors associated with …